This evening we watched Repligen rise 3.1% to a price of $127.0 per share. The Mid-Cap Biotechnology company is now trading -37.77% below its average target price of $204.08. Analysts have set target prices ranging from $165.0 to $225.0 per share for Repligen, and have given the stock an average rating of buy.
Repligen has an average level of shares sold short, at 9.1% of its total share float. The stock's short ratio (also called days to cover) is 8.27. Since 6.57% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Institutional investors own 102.4% of Repligen's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Repligen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Blackrock Inc. | 14% | 7,773,131 | $987,187,637 |
| 2024-03-31 | Vanguard Group Inc | 9% | 5,100,013 | $647,701,651 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 6% | 3,568,316 | $453,176,132 |
| 2024-03-31 | FMR, LLC | 4% | 2,257,789 | $286,739,203 |
| 2024-03-31 | State Street Corporation | 3% | 1,758,212 | $223,292,924 |
| 2024-03-31 | Macquarie Group Limited | 3% | 1,464,602 | $186,004,454 |
| 2024-03-31 | Sands Capital Management, LLC | 3% | 1,432,737 | $181,957,599 |
| 2024-03-31 | Invesco Ltd. | 2% | 1,242,743 | $157,828,361 |
| 2024-03-31 | Brown Capital Management, LLC | 2% | 1,154,635 | $146,638,645 |
| 2024-03-31 | Bank Of New York Mellon Corporation | 2% | 1,132,491 | $143,826,357 |
